Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02244294
Other study ID # 527.26
Secondary ID
Status Completed
Phase Phase 2
First received September 18, 2014
Last updated September 18, 2014
Start date March 2001

Study information

Verified date September 2014
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of six months of active treatment


Recruitment information / eligibility

Status Completed
Enrollment 176
Est. completion date
Est. primary completion date June 2005
Accepts healthy volunteers No
Gender Male
Age group 45 Years and older
Eligibility Inclusion Criteria:

Phase I

- Adult men, 45 years of age or older, diagnosed with acute urinary retention due to BPH

- Patients who have never taken alpha-blockers or discontinued taking alpha-blockers 72 hours or more prior to entrance into this study

- Patients that have been treated with an indwelling urethral catheter as treatment for acute urinary retention (AUR) due to BPH

- Patients must be judged by the investigator to be reliable and willing to comply with all tests and examinations stipulated in the protocol

- All patients must be willing to give meaningful, written, informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must also have sufficient understanding to communicate effectively with the investigator

Phase II - Patients who voided spontaneously, at least 100 mL and a post-void residual volume of = 300 mL, at Visit 2

Exclusion Criteria:

Phase I

- Patients diagnosed with a symptomatic/active urinary tract infection (UTI) or an abnormal urine culture at baseline or 2 or more UTIs within the last six months. An abnormal urine culture was defined as:

- A bacterial colony count of greater than or equal to 100,000 CFU/mL or

- A bacterial colony count of greater than or equal to 100 CFU/mL of a known urinary pathogen in a symptomatic patient

- Patients that have a distended bladder volume greater than 1.5 liters (1500 ml) of retention as measured by initial catheter urine volume

- Patients with history of sexually transmitted disease within last two years

- Patients with active genital herpes disease whose urinary function was impacted due to the disease

- Patients who have a history of mechanical outlet obstruction excluding BPH (i.e., bladder neck contracture or stricture, bladder tumor, or bladder calculi)

- Patients with urethral stricture disease

- Patients with a history of bladder, prostate, or urethral surgery in the last three months

- Patients presenting with AUR who were not been seen within 5 days of urethral catheter placement

- Patients presenting with any of the following: active urinary stone disease, previous pelvic radiotherapy, perirectal inflammatory disorders or inflammatory bowel disease

- Participation in another drug study within 30 days of Visit 1

- Clinically relevant conditions which may interfere with the patient's ability to participate in the study including, but not limited to, the following: neurologic, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, hematologic or respiratory disease and clinically relevant laboratory abnormalities not mentioned above (e.g., hematuria) based upon the clinical judgment of the investigator

- Patients receiving cimetidine, ranitidine or warfarin within two weeks of study start date and who would potentially use such medications during the course of the trial

- Patients currently treated with finasteride (PROSCAR®) and who would not discontinue its use upon entrance into the study

- Patients with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers

- Patients with a history of myocardial infarction within six months of baseline

- Patients with uncontrolled hypertension (systolic > 160 mmHg, diastolic > 100 mmHg) and patients with severe hypotension (systolic < 90 mmHg)

- Patients who have been using the following drugs, 72 hours prior to study start date, or who are unable to discontinue these drugs over the course of the study:

- Alpha-adrenergic medication

- Drugs with systemic anticholinergic activity including antihistamines. The following antihistamines are allowed: ALLEGRA®, CLARITIN® or ZYRTEX®

- Antispasmodics or muscle relaxants

- Parasympathomimetics, cholinomimetics or similar drug

- Patients that have poorly controlled diabetes mellitus who suffer from peripheral neuropathy or diabetic cystopathy

- Patients who suffer from neurological diseases affecting the bladder (i.e., multiple sclerosis, Parkinson's disease, stroke, and any bladder trauma that may be an exclusion criterion in the opinion of the investigator

- Patients with a neurological impairment or psychiatric disorder that prevents their comprehension of the informed consent and/or the ability to comply with the protocol

- Patients with a urine volume at the initial catheterization less than 300 mL

- Patients with a diagnosis of active cancer, except basal cell carcinoma, within 5 years or less

- Patients who had a transurethral resection of the prostate (TURP) within 5 years or less of study enrollment and irreversible urethral damage due to the procedure

Phase II

- Patients with clinically, significant abnormal lab results including any baseline laboratory serum test with the following values:

- Hemoglobin < 11.0 g/dL

- Leukocytes < 3,000 per mm3

- Liver enzymes [aspartate aminotransferase (SGOT), alanine transaminase (SGPT) and alkaline phosphatase]: more than two times the upper limit of normal at baseline

- Serum creatinine more than two times the upper limit of normal at Visit 1

- Patients with clot retention, persistent gross hematuria (Visit 3 only), prostatitis, a symptomatic/active urinary tract infection (UTI) or an abnormal baseline urine culture

- An abnormal urine culture was defined as:

- A bacterial colony count of greater than or equal to 100,000 colony forming units (CFU)/mL or

- A bacterial colony count of greater than or equal to 100 CFU/mL of a kown urinary pathogen in a symptomatic patient

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
FLOMAX® capsules

Placebo capsules


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Outcome

Type Measure Description Time frame Safety issue
Primary Successful spontaneous voiding after urethral catheter removal For Phase I of the trial Up to 96 hours after start of treatment No
Primary Maintenance of successful spontaneous voiding For Phase II of the trial Up to 6 months after start of treatment No
Secondary Change in voided urine volume Up to 6 months after start of treatment No
Secondary Determination of post-void residual urine volume by ultrasound or bladder scan Up to 6 months after start of treatment No
Secondary Time to recurrence of AUR For phase II of the trial Up to 6 months after start of treatment No
Secondary Clinically significant changes from baseline in vital signs Pre-dose, up to 6 months after start of treatment No
Secondary Number of patients with adverse events Up to 6 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05443451 - BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT05017285 - Ejaculation Preservation After Laser Enucleation Prostate N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05440981 - Implanted Nitinol Device (iTind) System in Chinese Males With Lower Urinary Tract Symptom Secondary to BPH N/A
Recruiting NCT05531240 - Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE) N/A
Recruiting NCT03176017 - Ejaculatory Sparing Transurethral Incision Of The Prostate (ES-TUIP) Versus Conventional TUIP N/A
Recruiting NCT03966950 - Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia N/A
Recruiting NCT06116851 - Prostate Metabolism, Cancer Risk and Gut Microbiota
Completed NCT04781985 - Prostatic Resection Cavity Stone Post Transurethral Resection of the Prostate (TURP). A Rare Case Scenario N/A
Not yet recruiting NCT01876836 - Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Phase 4
Not yet recruiting NCT05941260 - Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics
Completed NCT04580628 - Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)
Completed NCT04848181 - The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate Early Phase 1
Not yet recruiting NCT06224218 - Prostate Single Port & Laser Enucleation Comparison Trial N/A
Completed NCT04781049 - Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial N/A
Completed NCT05059431 - The Effect of Human Prostate Tissue on Platelet Activation
Completed NCT05108662 - Inflammatory Markers: HOLEP Versus TURP N/A
Completed NCT04275076 - HoLEP Vs BPEP for Large Prostatic Adenoma Phase 3

External Links